Welcome to our dedicated page for Neuroone Med Technologies SEC filings (Ticker: NMTC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Tracking FDA milestones and neuromodulation breakthroughs at NeuroOne Medical Technologies Corp often means digging through hundreds of technical pages. Whether you’re searching for capital-intensive R&D figures or the latest thin-film electrode patent updates, NeuroOne’s disclosures can feel overwhelming.
Stock Titan solves that problem. Our AI reads every new document the instant it hits EDGAR, then delivers clear takeaways you can act on. Need the NeuroOne Medical Technologies quarterly earnings report 10-Q filing? We tag revenue from clinical evaluations and spotlight changes in cash burn. Curious about NeuroOne Medical Technologies insider trading Form 4 transactions? Real-time alerts surface each executive purchase or sale so you can gauge management’s confidence. The platform also breaks down:
- NeuroOne Medical Technologies annual report 10-K simplified – see FDA submission timelines, manufacturing scale-up costs, and segment revenue in minutes.
- NeuroOne Medical Technologies 8-K material events explained – from pivotal trial results to licensing agreements, our summaries flag what moves the stock.
- NeuroOne Medical Technologies proxy statement executive compensation – understand option grants tied to device approvals without wading through tables.
All filings—10-K, 10-Q, 8-K, S-1, plus every NeuroOne Medical Technologies Form 4 insider transactions real-time—are updated automatically. Investors use our AI-powered summaries to compare quarter-over-quarter R&D spend, monitor patent additions, and track NeuroOne Medical Technologies executive stock transactions Form 4 before key announcements. If you’ve ever typed “understanding NeuroOne Medical Technologies SEC documents with AI” or looked for “NeuroOne Medical Technologies earnings report filing analysis,” you’re in the right place. Complex med-tech disclosures made clear—so you can focus on decision-making, not document hunting.
Form 4 filing overview: On 06/23/2025, NeuroOne Medical Technologies Corp. (NMTC) director Jeffrey S. Mathiesen received an option to purchase 50,000 shares of common stock at an exercise price of $0.662 per share. The option vests in twelve equal monthly installments over one year and carries an expiration date of 06/23/2035. Following the grant, Mathiesen now beneficially owns 50,000 derivative securities directly.
No open-market purchases or sales of common shares were reported, and no changes to previously held positions were disclosed. The transaction appears to be standard board compensation designed to align the director’s interests with shareholders while creating only modest potential dilution.
Nuveen Winslow Large-Cap Growth ESG ETF (NWLG) — Form NPORT-P
The document submitted to the SEC is a skeletal Form NPORT-P. It contains the required section headings (Part A-General Information, Part B-Fund Data, Items B.1-B.6, etc.), but virtually every quantitative and descriptive field—including total assets, liabilities, net assets, portfolio-level risk metrics, securities-lending details, monthly returns, derivative gains/losses, and share-flow information—is blank. Registrant name, CIK, LEI, address and series identifiers are likewise omitted.
The only definitive disclosure is that the submission is structured as a LIVE electronic filing; all other check-boxes (e.g., final-filing status) remain unmarked, and no contact information is provided. As a result, investors receive no insight into the ETF’s financial position, performance or risk profile for the reported period. The filing appears to be an incomplete or placeholder template rather than a finalized monthly portfolio report.
FAQ
What is the current stock price of Neuroone Med Technologies (NMTC)?
What is the market cap of Neuroone Med Technologies (NMTC)?
What is the core focus of NeuroOne Medical Technologies Corp?
Which neurological conditions are primarily addressed by NeuroOne's technologies?
How does NeuroOne generate revenue?
What makes the thin film electrode technology significant?
How does NeuroOne ensure compliance with regulatory standards?
What sets NeuroOne apart from its competitors in the neuromodulation market?
In what clinical environments are NeuroOne's products used?
What role does research and development play at NeuroOne?
